Table 2.
Details of treatment
| Parameter | All GBM | mEHT±SAT | Combination treatment | ddTMZ+mEHT | LD-mEHT | HD-mEHT | HD-mEHT <50 years |
|||||||
| (1) | (2) | (3) | (4) | (5) | (6) | (7) | ||||||||
| Value | % | Value | % | Value | % | Value | % | Value | % | Value | % | Value | % | |
| Time to first mEHT since diagnosis (months) | ||||||||||||||
| Mean | 12.1±1.6 | 11.2±2.3 | 12.3±1.9 | 12.9±2.1 | 13.3±2.4 | 11.5±2.0 | 12.7±4.2 | |||||||
| Median | 8.5 | 8.0 | 9.3 | 9.5 | 9.9 | 8.2 | 5.9 | |||||||
| Range | 0.2–94.2 | 2.3–44.1 | 0.2–94.2 | 0.2–94.2 | 1.6–49.1 | 0.2–94.2 | 1.0–94.2 | |||||||
| 95% CI | 6.7 to 10.6 | 6.1 to 15.2 | 5.8 to 10.7 | 5.9 to 10.7 | 6.1 to 11.6 | 5.1 to 10.0 | 4.1 to 10.0 | |||||||
| Earliest mEHT | 01 March 2001 | 07 May 2001 | 01 March 2001 | 01 March 2001 | 07 June 2001 | 01 March 2001 | 01 March 2001 | |||||||
| Latest mEHT | 20 May 2005 | 19 May 2005 | 20 May 2005 | 20 May 2005 | 28 April 2005 | 20 May 2005 | 20 May 2005 | |||||||
| Treatment combinations | ||||||||||||||
| mEHT+CRT+SAT | 2 | 3% | 0 | 0% | 2 | 3% | 0 | 0% | 0 | 0% | 2 | 4% | 0 | 0% |
| mEHT+chemoradiation | 1 | 1% | 0 | 0% | 1 | 2% | 0 | 0% | 0 | 0% | 1 | 2% | 1 | 4% |
| mEHT+chemotherapy+SAT | 43 | 57% | 0 | 0% | 43 | 74% | 43 | 80% | 12 | 50% | 31 | 60% | 13 | 57% |
| mEHT+radiation+SAT | 1 | 1% | 0 | 0% | 1 | 2% | 0 | 0% | 0 | 0% | 1 | 2% | 1 | 4% |
| mEHT+chemotherapy | 11 | 14% | 0 | 0% | 11 | 19% | 11 | 20% | 6 | 25% | 5 | 10% | 3 | 13% |
| mEHT+SAT | 13 | 17% | 13 | 72% | 0 | 0% | 0 | 0% | 4 | 17% | 9 | 17% | 5 | 22% |
| mEHT only | 5 | 7% | 5 | 28% | 0 | 0% | 0 | 0% | 2 | 8% | 3 | 6% | 0 | 0% |
| Treatment by modality | ||||||||||||||
| Radiation total | 4 | 5% | 0 | 0% | 4 | 7% | 0 | 0% | 0 | 0% | 4 | 8% | 2 | 9% |
| SAT total | 59 | 78% | 13 | 72% | 46 | 79% | 43 | 80% | 16 | 67% | 43 | 83% | 19 | 83% |
| Chemotherapy total | ||||||||||||||
| NOP | 57 | 75% | 0 | 0% | 57 | 98% | 54 | 100% | 18 | 75% | 39 | 75% | 17 | 74% |
| No. of cycles | 89 | 0 | 89 | 84 | 18 | 71 | 32 | |||||||
| Mean | 1.5±0.1 | 0 | 1.6±0.1 | 1.6±0.1 | 1.0±0.0 | 1.8±0.1 | 1.8±0.2 | |||||||
| Median | 1.0 | 1.0 | 1.0 | 1.0 | 1.0 | 1.5 | 2.0 | |||||||
| Range | 1.0–5.0 | 1.0–3.0 | 1.0–5.0 | 1.0–5.0 | 1.0–1.0 | 1.0–5.0 | 1.0–5.0 | |||||||
| 95% CI | 1.0 to 1.0 | 1.0 to 2.0 | 1.0 to 1.0 | 1.0 to 1.0 | 1.0 to 1.0 | 1.0 to 2.0 | 1.0 to 2.0 | |||||||
| mEHT total | ||||||||||||||
| NOP | 76 | 100% | 18 | 100% | 58 | 100% | 54 | 100% | 24 | 100% | 52 | 100% | 23 | 100% |
| No. of sessions | 1367 | 292 | 1075 | 995 | 169 | 1198 | 545 | |||||||
| Mean | 18.0±0.3 | 16.2±0.6 | 18.5±0.4 | 18.4±0.4 | 7.0±0.1 | 23.0±0.4 | 23.7±0.6 | |||||||
| Median | 14.0 | 13.5 | 14.0 | 14.0 | 7.0 | 18.0 | 23.0 | |||||||
| Range | 3.0–65.0 | 4.0–43.0 | 3.0–65.0 | 3.0–65.0 | 3.0–9.0 | 10.0–65.0 | 10.0–65.0 | |||||||
| 95% CI | 11.0 to 16.0 | 7.0 to 23.0 | 11.0 to 17.0 | 10.0 to 17.0 | 6.0 to 9.0 | 15.0 to 26.0 | 15.0 to 27.0 | |||||||
| Low-dose mEHT | 24 | 32% | 6 | 33% | 18 | 31% | 18 | 33% | 24 | 100% | 0 | 0% | 0 | 0% |
| Time of treatment (months) | ||||||||||||||
| Mean | 2.5±0.4 | 1.6±0.4 | 2.8±0.5 | 2.7±0.6 | 0.5±0.0 | 3.4±0.6 | 3.4±0.7 | |||||||
| Median | 1.1 | 1.0 | 1.1 | 1.1 | 0.5 | 1.9 | 1.9 | |||||||
| Range | 0.0–26.4 | 0.2–6.4 | 0.0–26.4 | 0.0–26.4 | 0.0–0.8 | 0.2–26.4 | 0.5–12.2 | |||||||
| 95% CI | 0.8 to 1.5 | 0.5 to 2.1 | 0.8 to 1.6 | 0.8 to 1.6 | 0.4 to 0.6 | 1.2 to 2.8 | 1.2 to 4.6 | |||||||
| p Value (t-test) | 0.233 | 0.001 | ||||||||||||
| Terminated (NOP) | 9 | 12% | 1 | 6% | 8 | 14% | 8 | 15% | 9 | 38% | 0 | 0% | 0 | 0% |
| p Value (χ2) | 0.35 | <0.0001 | 0.085* | |||||||||||
*Versus all GBM sample.
ddTMZ, dose-dense temozolomide; GBM, glioblastoma; HD, high dose; LD, low dose; mEHT, modulated electrohyperthermia; NOP, no. of patients; SAT, supportive and alternative treatments.